Search Results - Mark J. Levis

Refine Results
  1. 1
    FLT3/ITD AML and the law of unintended consequences

    FLT3/ITD AML and the law of unintended consequences by Mark J. Levis

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia

    Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia by Mark J. Levis

    Published 2014
    Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

    FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? by Mark J. Levis

    Published 2013
    Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Midostaurin approved for FLT3-mutated AML

    Midostaurin approved for FLT3-mutated AML by Mark J. Levis

    Published 2017
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    <i>FLT3</i>tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations

    <i>FLT3</i>tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations by Sabine Käyser, Mark J. Levis

    Published 2013
    Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    FLT3 inhibitors: a story of the old and the new

    FLT3 inhibitors: a story of the old and the new by Amir T. Fathi, Mark J. Levis

    Published 2011
    Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    Targeting FLT3 to treat leukemia

    Targeting FLT3 to treat leukemia by Helmut König, Mark J. Levis

    Published 2014
    Get full text
    Revisão
    Save to List
    Saved in:
  8. 8
    Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment

    Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment by Gabriel Ghiaur, Mark J. Levis

    Published 2017
    Get full text
    Revisão
    Save to List
    Saved in:
  9. 9
    Advances in targeted therapy for acute myeloid leukaemia

    Advances in targeted therapy for acute myeloid leukaemia by Sabine Käyser, Mark J. Levis

    Published 2017
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  10. 10
    Clinical implications of molecular markers in acute myeloid leukemia

    Clinical implications of molecular markers in acute myeloid leukemia by Sabine Käyser, Mark J. Levis

    Published 2018
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  11. 11
    Updates on targeted therapies for acute myeloid leukaemia

    Updates on targeted therapies for acute myeloid leukaemia by Sabine Käyser, Mark J. Levis

    Published 2021
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  12. 12
    The clinical impact of the molecular landscape of acute myeloid leukemia

    The clinical impact of the molecular landscape of acute myeloid leukemia by Sabine Käyser, Mark J. Levis

    Published 2023
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  13. 13
    FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance

    FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance by Michael R. Grunwald, Mark J. Levis

    Published 2013
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  14. 14
    Activation of the alpha subunit of Gs in intact cells alters its abundance, rate of degradation, and membrane avidity.

    Activation of the alpha subunit of Gs in intact cells alters its abundance, rate of degradation, and membrane avidity. by Mark J. Levis, Henry R. Bourne

    Published 1992
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Inhibition of c-Kit by tyrosine kinase inhibitors

    Inhibition of c-Kit by tyrosine kinase inhibitors by Αlex Galanis, Mark J. Levis

    Published 2014
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  16. 16
    How I treat FLT3-mutated AML

    How I treat FLT3-mutated AML by Keith W. Pratz, Mark J. Levis

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Gilteritinib: potent targeting of FLT3 mutations in AML

    Gilteritinib: potent targeting of FLT3 mutations in AML by Mark J. Levis, Alexander E. Perl

    Published 2020
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  18. 18
    Potential targeting of FLT3 acute myeloid leukemia

    Potential targeting of FLT3 acute myeloid leukemia by Alexander J. Ambinder, Mark J. Levis

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Bone marrow stroma‐mediated resistance to <scp>FLT</scp>3 inhibitors in <scp>FLT</scp>3‐<scp>ITD AML</scp> is mediated by persistent activation of extracellular regulated kinase

    Bone marrow stroma‐mediated resistance to <scp>FLT</scp>3 inhibitors in <scp>FLT</scp>3‐<scp>ITD AML</scp> is mediated by persistent activation of extracellular regulated kinase... by Xiaochuan Yang, Amy Sexauer, Mark J. Levis

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond

    The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond by Seth A. Wander, Mark J. Levis, Amir Fathi

    Published 2014
    Get full text Get full text
    Revisão
    Save to List
    Saved in:

Search Tools: